Dana-Farber Cancer Institute
Leslie S. Kean, M.D., Ph.D., is the Stranahan Professor of Pediatrics at Harvard Medical School, Director of the Pediatric Stem Cell Transplant Program at Boston Children’s Hospital/Dana-Farber Cancer Institute, and Chair of the Pediatric Transplantation and Cellular Therapies Consortium (PTCTC). Dr. Kean’s research program is focused on the immunology of hematopoietic stem cell transplantation, tolerance-induction for solid organ transplantation through cellular therapeutics, and immune tolerance in allo- and auto-immune diseases. The overarching goal is to understand mechanisms underlying immune tolerance, with a specific focus on graft-versus-host disease (GvHD), mixed-chimerism induction for solid organ transplantation, transplant rejection, the immunology of gastrointestinal auto-immune diseases, and the reconstitution of protective immunity after transplantation. Her team has used the animal models, clinical trial-linked mechanistic studies and state-of-the single-cell transcriptomic and computational methodologies to investigate the cellular and molecular mechanisms of immune reconstitution, GvHD, transplant rejection and Inflammatory Bowel Disease, and to test the impact that novel immunomodulatory therapies can make on these processes. Dr. Kean’s work has led to the creation of multiple novel, non-human primate models of both engraftment and GvHD, several first-in-disease clinical trials, and the recent FDA approval of abatacept for GVHD prevention, which represents the first FDA approval for this indication.
Presentation Abstract: From Bench to Bedside to the FDA: T Cell Costimulation Blockade for the Prevention of Acute GVHD